In a switch, Merck CEO signals he’s in a deal-making frame of mind
Over the last few years, Merck’s big R&D group has been concentrating heavily on its PD-1 superstar Keytruda, for obvious reasons. After jumping in as the number two player behind Bristol-Myers, the pharma giant wanted to take the lead — and it did.
Major new deals were put on the back burner, until recently.
But now the company is changing its tune, and there could be significant implications for the industry. Merck CEO Ken Frazier led his Q3 report on the numbers with what for him is an unusually bold comment:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.